Afamelanotide Suppliers & Bulk Manufacturers
Available Forms: Subcutaneous implant
Available Strengths: 16 mg
Reference Brands: Scenesse (USA)
Category:
Derma Drugs
Afamelanotide is available in Subcutaneous implant
and strengths such as 16 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Afamelanotide is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Afamelanotide can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Afamelanotide is a synthetic peptide medication used to prevent phototoxic reactions and reduce pain caused by light exposure in patients with erythropoietic protoporphyria (EPP), a rare genetic photosensitivity disorder. It is marketed under the brand name Scenesse and is administered as a prolonged-release subcutaneous implant.
Afamelanotide acts as an agonist of the melanocortin-1 (MC1) receptor and is an analogue of the naturally occurring alpha-melanocyte-stimulating hormone (α-MSH). By mimicking the biological activity of α-MSH, afamelanotide stimulates melanocytes in the skin to increase the production and release of melanin. Elevated melanin levels enhance the skin’s tolerance to visible and ultraviolet light exposure.
The increased melanin provides photoprotective effects by reducing ultraviolet radiation-induced cellular DNA damage, limiting oxidative stress on membrane proteins, and helping maintain normal intracellular signaling processes in epidermal cells. Under physiological conditions, α-MSH is released by skin cells in response to ultraviolet radiation; afamelanotide replicates this protective mechanism in patients with impaired photoprotection.
Afamelanotide offers an effective preventive treatment option for managing light-induced pain and improving quality of life in individuals affected by erythropoietic protoporphyria.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing